↓ Skip to main content

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

Overview of attention for article published in Trials, May 2022
Altmetric Badge

Mentioned by

twitter
15 X users

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
Published in
Trials, May 2022
DOI 10.1186/s13063-022-06370-1
Pubmed ID
Authors

Nicholas A. Turner, Smitha Zaharoff, Heather King, Scott Evans, Toshimitsu Hamasaki, Thomas Lodise, Varduhi Ghazaryan, Tatiana Beresnev, Todd Riccobene, Rinal Patel, Sarah B. Doernberg, Urania Rappo, Vance G. Fowler, Thomas L. Holland

X Demographics

X Demographics

The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 21%
Student > Master 2 8%
Student > Ph. D. Student 2 8%
Student > Doctoral Student 1 4%
Researcher 1 4%
Other 1 4%
Unknown 12 50%
Readers by discipline Count As %
Medicine and Dentistry 5 21%
Pharmacology, Toxicology and Pharmaceutical Science 3 13%
Nursing and Health Professions 2 8%
Immunology and Microbiology 1 4%
Unknown 13 54%